Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

Table 5 Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole (CTX) or norfloxacin (NFX)

Study	Nitroxoline	Control	Indication	Patients (n)	Duration	End of therapy visit	Test of cure visit
NWNF 10°	Nitroxoline (NTX)	Cotrimoxazole (CTX)	Acute uncompl. cystitis	130 total	5 days	day 6	day 12–14
NWNF 10°	3×250 mg	2×960 mg		67 NTX, 63 CTX	5 days	day 6	day 12–14
NWNF 11	Nitroxoline (NTX)	Cotrimoxazole (CTX)	Acute uncompl. cystitis	115 total	5 days	day 6	day 12–14
	3×250 mg	2×960 mg		56 NTX
	3×250 mg	2×960 mg		59 CTX
NWNF 13	Nitroxoline (NTX)	Norfloxacin (NFX)	Acute uncompl. cystitis	105 total	5 days	day 6	day 12–14
	3×250 mg	2×400 mg		51 NTX
	3×250 mg	2×400 mg		54 NFX
NWNF 15	Nitroxoline (NTX)	Cotrimoxazole (CTX)	Acute episode of uncompl. recurrent cystitis	116 total	10 days	day 11–13*	day 21–23
	3×250 mg	2×960 mg		60 NTX
	3×250 mg	2×960 mg		56 CTX

°inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).
*additional visit during therapy: day 6–8.

ISSN: 1471-2334